Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit

Data ReadoutpositivePRPPositive

AI Analysis

Summary

Propanc Biopharma announced preclinical data for PRP demonstrating >90% tumor growth inhibition and >2.5-fold survival benefit in pancreatic cancer models using a non-cytotoxic, differentiation-based approach.

Outcome Details

>90% tumor growth inhibition and >2.5-fold survival benefit in preclinical pancreatic cancer model

Importance:5/10

Sentiment:

0.70

pancreatic cancerpreclinical datadifferentiation-based therapytumor inhibitionsurvival benefit

Related Companies

$PPCB

Read the original article

Published by GlobeNewswire Clinical Studies on August 27, 2026 12:30 PM

Read Original